skip to main content
1800 500 258

Latest news

Find the latest news and information from BCNA

No PBS listing for new breast cancer drugs ribociclib and palbociclib

BCNA News 21 Aug 2017

No PBS listing for new breast cancer drugs ribociclib and palbociclib

The Pharmaceutical Benefits Advisory Committee* (PBAC) has recommended to the Australian Government that the new breast cancer drug ribociclib (Kisqali) not be listed on the Pharmaceutical Benefits Scheme (PBS). This follows its decision earlier this year to not recommend palbociclib (Ibrance) be added to the PBS. Read more